WEI-WU HE, Ph.D. 13D and 13G filings for CASI Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-06-20 4:30 pm Purchase |
2025-06-16 | 13D | CASI Pharmaceuticals, Inc. CASI |
WEI-WU HE, Ph.D. | 3,735,535 23.800% |
477,644 (+14.66%) |
Filing |
| 2024-08-12 08:27 am Purchase |
2024-07-15 | 13D | CASI Pharmaceuticals, Inc. CASI |
WEI-WU HE, Ph.D. | 3,257,891 20.940% |
420,000 (+14.80%) |
Filing |
| 2023-04-18 4:00 pm Purchase |
2023-04-14 | 13D | CASI Pharmaceuticals, Inc. CASI |
WEI-WU HE, Ph.D. | 2,837,891 19.750% |
2,837,891 (New Position) |
Filing |